Immunome (IMNM) investor relations material

Strategic vision and leadership

• Focus on building a premier oncology company with a robust pipeline of targeted therapies for cancer, including gamma secretase inhibitors and ADCs.

• Leadership team includes experienced professionals with a track record in successful drug development.

• Emphasis on both internal discovery and disciplined business development to drive innovation.

• Long-term goal is to deliver transformative cancer drugs to patients globally.

Pipeline highlights and clinical progress

• Varigastat, a once-daily gamma secretase inhibitor for desmoid tumors, is in phase 3 with top-line data expected in the second half of the year.

• Phase 2 data for varigastat showed higher potency and better response rates compared to the current standard, with a favorable safety profile.

• The phase 3 trial is randomized, double-blind, and placebo-controlled, with key endpoints including PFS and ORR.

• Regulatory guidance and event-driven unblinding strategies are being followed for data disclosure.

ADC technology and innovation

• First ADC candidate, targeting ROR1 (IM-1021), leverages proprietary payload and rapid internalization for enhanced efficacy.

• Preclinical and early clinical data show strong activity in both B-cell lymphomas and solid tumors.

• ADC platform uses a novel topo I inhibitor payload (HC-74) designed to overcome resistance and improve therapeutic index.

• Three additional ADCs are expected to be filed as INDs in 2026, with a focus on unique, underexploited targets.